STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBIO
  4. [Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

BridgeBio (BBIO) director sells 8,671 shares after exercising stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BridgeBio Pharma director Hannah Valantine exercised stock options to acquire 8,671 shares of common stock at $27.36 per share on March 10, 2026. She then sold the same 8,671 shares at $72.00 per share in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she holds 7,465 shares directly and 398 shares indirectly through her spouse.

Positive

  • None.

Negative

  • None.

Insights

Director exercised options then sold the acquired shares under a 10b5-1 plan, retaining a meaningful equity stake.

Hannah Valantine, a director of BridgeBio Pharma, exercised stock options for 8,671 shares of common stock at an exercise price of $27.36 per share, then sold the same 8,671 shares at $72.00 per share on March 10, 2026. This pattern is a classic exercise-and-sell sequence that converts option value into cash.

The filing notes the sale was executed under a pre-arranged Rule 10b5-1 sales plan adopted on November 14, 2025, indicating the timing was planned rather than opportunistic. After the transactions, Valantine directly owns 7,465 shares of common stock and indirectly holds 398 shares through her spouse, so she maintains ongoing equity exposure alongside the monetization.

Insider Valantine Hannah
Role Director
Sold 8,671 shs ($624K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 8,671 $0.00 --
Exercise Common Stock 8,671 $27.36 $237K
Sale Common Stock 8,671 $72.00 $624K
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 17,343 shares (Direct); Common Stock — 16,136 shares (Direct); Common Stock — 398 shares (Indirect, By Spouse)
Footnotes (1)
  1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025. One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Valantine Hannah
(Last) (First) (Middle)
C/O BRIDGEBIO PHARMA, INC.
3160 PORTER DR., SUITE 250
(Street)
PALO ALTO CA 94304
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/10/2026 M 8,671 A $27.36 16,136 D
Common Stock 03/10/2026 S(1) 8,671 D $72 7,465 D
Common Stock 398 I By Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $27.36 03/10/2026 M 8,671 (2) 06/20/2034 Common Stock 8,671 $0 17,343 D
Explanation of Responses:
1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.
2. One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer.
Remarks:
/s/ Will Solis, Attorney-in-Fact 03/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did BridgeBio Pharma (BBIO) director Hannah Valantine do in this Form 4?

Director Hannah Valantine exercised stock options to acquire 8,671 BridgeBio shares at $27.36 each, then sold the same 8,671 shares at $72.00. These transactions were reported for March 10, 2026.

Was the BridgeBio (BBIO) insider sale by Hannah Valantine pre-planned?

Yes. The filing states the 8,671-share sale at $72.00 per share was executed under a Rule 10b5-1 sales plan adopted on November 14, 2025, indicating the trade timing was established in advance.

How many BridgeBio (BBIO) shares did Hannah Valantine sell and at what price?

Hannah Valantine sold 8,671 shares of BridgeBio common stock at $72.00 per share. These shares had just been acquired through a stock option exercise at an exercise price of $27.36 per share on the same date.

How many BridgeBio (BBIO) shares does Hannah Valantine own after these transactions?

After the reported transactions, Hannah Valantine directly owns 7,465 BridgeBio common shares. She also has an indirect holding of 398 shares through her spouse, giving her continued exposure to the company’s equity.

What type of stock option did the BridgeBio (BBIO) director exercise?

She exercised a Stock Option (Right to Buy) covering 8,671 underlying BridgeBio common shares at an exercise price of $27.36. The option was scheduled to vest in three equal annual installments through June 21, 2027.

Does Hannah Valantine still hold derivatives in BridgeBio (BBIO) after this Form 4?

The filing shows an option exercise for 8,671 underlying shares and no remaining derivative positions listed in the derivative summary. Post-transaction ownership is reflected only in common stock, both direct and indirect through her spouse.